Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


29.10.2018

1 Am J Respir Crit Care Med
1 Ann Oncol
3 Ann Thorac Surg
3 BMC Cancer
3 BMJ
1 Cancer
2 Cancer Lett
1 Cancer Res
1 Carcinogenesis
1 Chest
2 Clin Cancer Res
1 Clin Exp Metastasis
5 Clin Lung Cancer
1 Eur J Cancer
1 Eur Respir J
1 Genes Chromosomes Cancer
3 Int J Oncol
1 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
3 J Clin Oncol
2 J Thorac Oncol
1 Lung Cancer
1 Mol Cancer Ther
2 Mol Carcinog
3 Oncogene
4 Oncol Rep
4 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. KIM HR, Park SM, Seo SU, Jung I, et al
    The Ratio of Peripheral Regulatory T Cells to Lox-1(+) PMN-MDSC Predicts the Early Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer Patients.
    Am J Respir Crit Care Med. 2018 Oct 19. doi: 10.1164/rccm.201808-1502.
    PubMed     Text format    


    Ann Oncol

  2. WAN Y, Liu B, Lei H, Zhang B, et al
    Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer.
    Ann Oncol. 2018 Oct 18. pii: 5136413. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  3. RIQUET M, Arame A, Pricopi C
    Subcarinal Lymph Node Importance Revisited.
    Ann Thorac Surg. 2018;105:666-667.
    PubMed     Text format    

  4. GHALY G, Harrison S, Kamel MK, Rahouma M, et al
    Predictors of Survival After Treatment of Oligometastases After Esophagectomy.
    Ann Thorac Surg. 2017 Dec 21. pii: S0003-4975(17)31410.
    PubMed     Text format     Abstract available

  5. SADDOUGHI SA, Abdelsattar ZM, Blackmon SH
    National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
    Ann Thorac Surg. 2018;105:432-437.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. SCHERPEREEL A, Durand-Zaleski I, Cotte FE, Fernandes J, et al
    Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
    BMC Cancer. 2018;18:1013.
    PubMed     Text format     Abstract available

  7. IEZZI A, Caiola E, Scagliotti A, Broggini M, et al
    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.
    BMC Cancer. 2018;18:1028.
    PubMed     Text format     Abstract available

  8. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Text format     Abstract available


    BMJ

  9. KMIETOWICZ Z
    ACE inhibitors are linked to increased lung cancer risk, study finds.
    BMJ. 2018;363:k4471.
    PubMed     Text format    

  10. HICKS BM, Filion KB, Yin H, Sakr L, et al
    Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.
    BMJ. 2018;363:k4209.
    PubMed     Text format     Abstract available

  11. CRONIN-FENTON D
    Angiotensin converting enzyme inhibitors and lung cancer.
    BMJ. 2018;363:k4337.
    PubMed     Text format    


    Cancer

  12. STINCHCOMBE TE, Fan W, Schild SE, Vokes EE, et al
    A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31813.
    PubMed     Text format     Abstract available


    Cancer Lett

  13. WANG Z, Fu S, Zhao J, Zhao W, et al
    Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer.
    Cancer Lett. 2018 Oct 19. pii: S0304-3835(18)30628.
    PubMed     Text format     Abstract available

  14. GRUNDEMANN C, Huber R
    Chemoprevention with isothiocyanates - From bench to bedside.
    Cancer Lett. 2018;414:26-33.
    PubMed     Text format     Abstract available


    Cancer Res

  15. EL KADI N, Wang L, Davis A, Korkaya H, et al
    The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer.
    Cancer Res. 2018 Oct 17. pii: 0008-5472.CAN-17-3370.
    PubMed     Text format     Abstract available


    Carcinogenesis

  16. SCHELCH K, Wagner C, Hager S, Pirker C, et al
    FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
    Carcinogenesis. 2018;39:534-545.
    PubMed     Text format     Abstract available


    Chest

  17. TANNER NT, Silvestri GA
    Shared Decision Making and Lung Cancer Screening: Let's get the conversation started.
    Chest. 2018 Oct 22. pii: S0012-3692(18)32595-9. doi: 10.1016/j.chest.2018.
    PubMed     Text format    


    Clin Cancer Res

  18. SUZAWA K, Offin M, Lu D, Kurzatkowski C, et al
    Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1640.
    PubMed     Text format     Abstract available

  19. TAO Z, McCall NS, Wiedemann N, Vuagniaux G, et al
    SMAC mimetic Debio 1143 and ablative radiation therapy synergize to enhance anti-tumor immunity against lung cancer.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-17-3852.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  20. LIU W, Wu J
    Lung cancer with bone metastases in the United States: an analysis from the Surveillance, Epidemiologic, and End Results database.
    Clin Exp Metastasis. 2018 Oct 19. pii: 10.1007/s10585-018-9943.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  21. KSIENSKI D, Wai ES, Croteau N, Fiorino L, et al
    Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Clin Lung Cancer. 2018 Sep 22. pii: S1525-7304(18)30250.
    PubMed     Text format     Abstract available

  22. SCHONEWOLF CA, Heskel M, Doucette A, Singhal S, et al
    Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Clin Lung Cancer. 2018 Sep 20. pii: S1525-7304(18)30237.
    PubMed     Text format     Abstract available

  23. RICE SR, Molitoris JK, Vyfhuis MAL, Edelman MJ, et al
    Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.
    Clin Lung Cancer. 2018 Sep 24. pii: S1525-7304(18)30259.
    PubMed     Text format     Abstract available

  24. MENG X, Gao Y, Yang L, Jing H, et al
    Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Clin Lung Cancer. 2018 Sep 24. pii: S1525-7304(18)30257.
    PubMed     Text format     Abstract available

  25. ELAMIN YY, Gomez DR, Antonoff MB, Robichaux JP, et al
    Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2018 Sep 24. pii: S1525-7304(18)30260.
    PubMed     Text format     Abstract available


    Eur J Cancer

  26. SCHIEFER M, Hendriks LEL, Dinh T, Lalji U, et al
    Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
    Eur J Cancer. 2018;91:92-98.
    PubMed     Text format     Abstract available


    Eur Respir J

  27. RICH AL, Baldwin DR, Beckett P, Berghmans T, et al
    ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe.
    Eur Respir J. 2018 Oct 25. pii: 13993003.00610-2018.
    PubMed     Text format     Abstract available


    Genes Chromosomes Cancer

  28. WU SG, Liu YN, Yu CJ, Yang JC, et al
    Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
    Genes Chromosomes Cancer. 2018;57:513-521.
    PubMed     Text format     Abstract available


    Int J Oncol

  29. ZHANG X, Zhang X, Liu X, Qi P, et al
    MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer.
    Int J Oncol. 2018 Oct 19. doi: 10.3892/ijo.2018.4599.
    PubMed     Text format     Abstract available

  30. KANG MA, Kim W, Jo HR, Shin YJ, et al
    Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS032, on cervical cancer.
    Int J Oncol. 2018 May 31. doi: 10.3892/ijo.2018.4424.
    PubMed     Text format     Abstract available

  31. SUDO H, Tsuji AB, Sugyo A, Okada M, et al
    Direct comparison of 2amino[311C]isobutyric acid and 2amino[11C]methylisobutyric acid uptake in eight lung cancer xenograft models.
    Int J Oncol. 2018 Oct 16. doi: 10.3892/ijo.2018.4596.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  32. YILMAZ U, Wong TZ, Marks LB
    How Good Is Positron Emission Tomography at Detecting Previously-Occult Metastatic Lung Cancer at Diagnosis?
    Int J Radiat Oncol Biol Phys. 2018;102:716-717.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  33. YANG H, Xu J, Yao F, Liang S, et al
    Analysis of unexpected small cell lung cancer following surgery as the primary treatment.
    J Cancer Res Clin Oncol. 2018 Oct 20. pii: 10.1007/s00432-018-2766.
    PubMed     Text format     Abstract available


    J Clin Oncol

  34. RUSTHOVEN CG
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: The Costs Outweigh the Benefits.
    J Clin Oncol. 2018 Oct 22:JCO1800732. doi: 10.1200/JCO.18.00732.
    PubMed     Text format    

  35. ADDEO A, Caparrotti F, Picardi C, Dietrich PY, et al
    Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.
    J Clin Oncol. 2018 Oct 22:JCO1800461. doi: 10.1200/JCO.18.00461.
    PubMed     Text format    

  36. ZENG H, Yuan S, Yu J
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: Hope or Hype?
    J Clin Oncol. 2018 Oct 22:JCO1800617. doi: 10.1200/JCO.18.00617.
    PubMed     Text format    


    J Thorac Oncol

  37. LAMMERS A, Slatore CG, Fromme EK, Vranas K, et al
    Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer : A National Cohort Study.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33184.
    PubMed     Text format    

  38. BASU ROY U, King-Kallimanis BL, Kluetz PG, Selig W, et al
    Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33052.
    PubMed     Text format    


    Lung Cancer

  39. LUCCHESI C, Drogat B, Santamaria D, Cousin S, et al
    Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lung Cancer. 2018 Oct 12. pii: S0169-5002(18)30597.
    PubMed     Text format    


    Mol Cancer Ther

  40. ABOUBAKAR NANA F, Lecocq M, Ladjemi MZ, Detry B, et al
    Therapeutic potential of Focal Adhesion Kinase inhibition in small cell lung cancer.
    Mol Cancer Ther. 2018 Oct 23. pii: 1535-7163.MCT-18-0328.
    PubMed     Text format     Abstract available


    Mol Carcinog

  41. SONG JM, Im J, Nho RS, Han YH, et al
    Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.
    Mol Carcinog. 2018 Oct 26. doi: 10.1002/mc.22930.
    PubMed     Text format     Abstract available

  42. JIAN M, Yunjia Z, Zhiying D, Yanduo J, et al
    Interleukin 7 Receptor Activates PI3K/Akt/mTOR Signaling Pathway via Downregulation of Beclin-1 in Lung Cancer.
    Mol Carcinog. 2018 Oct 26. doi: 10.1002/mc.22933.
    PubMed     Text format     Abstract available


    Oncogene

  43. LEONG TL, Gayevskiy V, Steinfort DP, De Massy MR, et al
    Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.
    Oncogene. 2018 Oct 22. pii: 10.1038/s41388-018-0536.
    PubMed     Text format     Abstract available

  44. ORTH M, Unger K, Schoetz U, Belka C, et al
    Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
    Oncogene. 2018;37:52-62.
    PubMed     Text format     Abstract available

  45. CHIANG WF, Cheng TM, Chang CC, Pan SH, et al
    Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation.
    Oncogene. 2018;37:116-127.
    PubMed     Text format     Abstract available


    Oncol Rep

  46. FENG L, Yang Y, Li M, Song J, et al
    Systems biology analysis of the lung cancerrelated secretome.
    Oncol Rep. 2018;40:1103-1118.
    PubMed     Text format     Abstract available

  47. OTANI T, Kondo K, Takizawa H, Kajiura K, et al
    Noninvasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDGPET/CT and CT.
    Oncol Rep. 2018 Oct 24. doi: 10.3892/or.2018.6818.
    PubMed     Text format     Abstract available

  48. PARK SE, Kim DE, Kim MJ, Lee JS, et al
    Vorinostat enhances gefitinibinduced cell death through reactive oxygen speciesdependent cleavage of HSP90 and its clients in nonsmall cell lung cancer with the EGFR mutation.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6814.
    PubMed     Text format     Abstract available

  49. WANG N, Wang L, Meng X, Wang J, et al
    Osimertinib (AZD9291) increases radiosensitivity in EGFR T790M nonsmall cell lung cancer.
    Oncol Rep. 2018 Oct 17. doi: 10.3892/or.2018.6803.
    PubMed     Text format     Abstract available


    PLoS One

  50. LASITHIOTAKI I, Tsitoura E, Samara KD, Trachalaki A, et al
    NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer.
    PLoS One. 2018;13:e0205242.
    PubMed     Text format     Abstract available

  51. KHUNGER M, Patil PD, Khunger A, Li M, et al
    Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    PLoS One. 2018;13:e0197743.
    PubMed     Text format     Abstract available

  52. HART GR, Roffman DA, Decker R, Deng J, et al
    A multi-parameterized artificial neural network for lung cancer risk prediction.
    PLoS One. 2018;13:e0205264.
    PubMed     Text format     Abstract available

  53. LU S, Yu Y, Fu S, Ren H, et al
    Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    PLoS One. 2018;13:e0205827.
    PubMed     Text format     Abstract available


    Thorax

  54. BRUSTLE K, Zachariassen K, Vrugt B, Frauenfelder T, et al
    Acute pulmonary embolism and multiple pulmonary nodules mimicking metastatic disease.
    Thorax. 2018;73:193-194.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: